Shares of Vivos Therapeutics (NASDAQ: VVOS) shot up by more than 200% on Wednesday after the medical technology company announced that the U.S. FDA had cleared its proprietary DNA appliance (daytime-nighttime appliance) as a Class II device. This device can be used in the treatment for mild-to-moderate obstructive sleep apnea (OSA).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
With this clearance, VVOS’s device has given rise to “a completely new treatment regimen for mild-to-moderate OSA.” The company also expects that the FDA clearance “will now increase the ease of adoption of the DNA for treating OSA.”
But even with the rise in stock price today, in the past year, the stock has declined by 67.3%.
